CELU vs. XBI

In the year-to-date period, CELU achieves a 1.44% return, which is significantly higher than XBI's -12.06% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Celularity Inc. (CELU) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CELU Sharpe Ratio is -0.19, which is higher than the XBI Sharpe Ratio of -0.39. The chart below compares the historical Sharpe Ratios of CELU and XBI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

CELU has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.17%.

The maximum CELU drawdown since its inception was -99.16%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for CELU and XBI.

Celularity Inc. (CELU) has a higher volatility of 36.16% compared to SPDR S&P Biotech ETF (XBI) at 10.41%. This indicates that CELU's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.